Grandfield & Dodd LLC Makes New Investment in Zimmer Biomet Holdings, Inc. $ZBH

Grandfield & Dodd LLC acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 11,539 shares of the medical equipment provider’s stock, valued at approximately $993,000.

Several other institutional investors have also added to or reduced their stakes in ZBH. Main Management ETF Advisors LLC lifted its holdings in shares of Zimmer Biomet by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after purchasing an additional 112 shares in the last quarter. Citizens National Bank Trust Department boosted its holdings in shares of Zimmer Biomet by 17.6% in the 1st quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 141 shares during the last quarter. Oppenheimer & Co. Inc. lifted its stake in Zimmer Biomet by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 20,363 shares of the medical equipment provider’s stock valued at $1,831,000 after acquiring an additional 152 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Zimmer Biomet by 15.3% during the fourth quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock worth $104,000 after purchasing an additional 153 shares during the period. Finally, Leonteq Securities AG boosted its stake in shares of Zimmer Biomet by 5.3% during the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock worth $277,000 after acquiring an additional 153 shares during the period. 88.89% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Sang Yi sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider directly owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.28% of the stock is owned by insiders.

Zimmer Biomet Stock Down 2.5%

Shares of NYSE ZBH opened at $98.13 on Tuesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69. The company has a market capitalization of $18.72 billion, a P/E ratio of 23.88, a price-to-earnings-growth ratio of 3.20 and a beta of 0.45. The company’s 50 day moving average price is $91.72 and its 200-day moving average price is $90.65. Zimmer Biomet Holdings, Inc. has a 52-week low of $79.12 and a 52-week high of $108.29.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, topping analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The firm had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. During the same period last year, the business posted $2.07 EPS. The business’s revenue was up 4.8% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, July 31st. Shareholders of record on Thursday, June 25th were issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date was Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 23.36%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several research analyst reports. Barclays reduced their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating for the company in a report on Wednesday, April 29th. UBS Group restated a “buy” rating and issued a $120.00 price target on shares of Zimmer Biomet in a research report on Thursday, August 6th. Wells Fargo & Company lowered their price objective on shares of Zimmer Biomet from $98.00 to $90.00 and set an “equal weight” rating for the company in a research report on Wednesday, April 29th. Weiss Ratings raised Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, August 4th. Finally, Truist Financial increased their price target on Zimmer Biomet from $92.00 to $106.00 and gave the company a “hold” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, thirteen have assigned a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $104.42.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.